Company / SG&A Expense
PharmaCyte Biotech, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$6.1M
FY2025
5-year range
$418.1K / $6.1M
FY2021-FY2025
Trend
+449.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense changed +449% YoY in FY2025, a notable deviation from the 9-year average annual change of +67%.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +34.7%.
Increased from $1M to $6M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +144.5%
- 5-Year CAGR
- +34.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- PharmaCyte Biotech, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +34.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 449.4% year-over-year.
- Lowest sg&a expense in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.1M | +449.4% |
| FY2024 | $1.1M | +2.0% |
| FY2023 | $1.1M | +160.8% |
| FY2022 | $418.1K | -64.0% |
| FY2021 | $1.2M | -15.7% |
| FY2020 | $1.4M | -24.2% |
| FY2019 | $1.8M | +144.2% |
| FY2018 | $744.8K | -67.5% |
| FY2017 | $2.3M | +19.5% |
| FY2016 | $1.9M | +210.7% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026